Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$80.45
+0.6%
$78.96
$70.22
$109.00
$77.90B0.7990,017 shs26,158 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$537.85
-1.7%
$549.38
$476.49
$1,211.20
$57.87B0.33905,351 shs381,363 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$460.25
+0.1%
$450.84
$377.85
$519.88
$117.75B0.411.42 million shs576,718 shs
Zoetis Inc. stock logo
ZTS
Zoetis
$157.94
-0.8%
$161.16
$139.70
$200.33
$70.15B0.912.57 million shs1.08 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.00%+3.76%+1.27%+9.01%-20.99%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+4.61%+10.50%-4.85%-47.30%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%+3.02%+0.92%-4.20%-4.20%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%+1.94%-6.44%+6.82%-9.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.9639 of 5 stars
0.03.01.70.01.20.01.3
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.9537 of 5 stars
4.45.01.72.33.31.71.9
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4.7698 of 5 stars
3.35.00.03.34.02.51.3
Zoetis Inc. stock logo
ZTS
Zoetis
4.8385 of 5 stars
3.55.04.20.43.12.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
4.00
Strong BuyN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.80
Moderate Buy$813.5751.26% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.54
Moderate Buy$511.6211.16% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
3.00
Buy$212.1334.30% Upside

Current Analyst Ratings Breakdown

Latest VRTX, CSLLY, REGN, and ZTS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$550.00
6/20/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.00
6/18/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$165.00 ➝ $160.00
6/17/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$423.00 ➝ $420.00
6/9/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.00
6/5/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$700.00 ➝ $650.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.00
5/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$14.80B5.26$4.00 per share20.10$20.07 per share4.01
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.20B4.09$44.90 per share11.98$268.50 per share2.00
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.10B10.65N/AN/A$63.72 per share7.22
Zoetis Inc. stock logo
ZTS
Zoetis
$9.26B7.60$7.02 per share22.51$10.57 per share14.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$2.64BN/A0.0019.671.73N/AN/AN/A8/19/2025 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$39.2813.6514.152.0031.94%15.27%11.93%8/1/2025 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$3.92N/A26.29N/A-8.91%-3.36%-2.42%7/30/2025 (Estimated)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.49B$5.5728.2923.402.6427.12%55.48%19.14%8/5/2025 (Estimated)

Latest VRTX, CSLLY, REGN, and ZTS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q2 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.53N/AN/AN/A$3.30 billionN/A
5/6/2025Q1 2025
Zoetis Inc. stock logo
ZTS
Zoetis
$1.40$1.48+$0.08$1.41$2.20 billion$2.22 billion
5/5/2025Q1 2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion
4/29/2025Q1 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
$1.201.49%N/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.520.65%N/A8.96%N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.001.27%N/A35.91%14 Years

Latest VRTX, CSLLY, REGN, and ZTS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/22/2025
Zoetis Inc. stock logo
ZTS
Zoetis
quarterly$0.501.2%7/18/20257/18/20259/3/2025
5/20/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.6%5/20/20255/20/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.45
1.86
0.85
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.93
4.03
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.65
2.29
Zoetis Inc. stock logo
ZTS
Zoetis
1.12
1.74
1.04

Institutional Ownership

CompanyInstitutional Ownership
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
0.03%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7.02%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
Zoetis Inc. stock logo
ZTS
Zoetis
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
CSL Limited Sponsored ADR stock logo
CSLLY
CSL
32,698968.42 millionN/ANot Optionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,106107.96 million100.39 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,100256.80 million256.28 millionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
13,800445.21 million444.50 millionOptionable

Recent News About These Companies

Argentarii LLC Trims Stake in Zoetis Inc. (NYSE:ZTS)
2 Dividend Growth Stocks to Buy and Hold Forever

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSL stock logo

CSL OTCMKTS:CSLLY

$80.45 +0.49 (+0.61%)
As of 12:58 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$538.07 -9.29 (-1.70%)
As of 01:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$460.46 +0.84 (+0.18%)
As of 01:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Zoetis stock logo

Zoetis NYSE:ZTS

$158.04 -1.14 (-0.72%)
As of 01:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.